Skip to main content

RheumNow Week in Review – 7 October 2016

Oct 07, 2016 2:53 pm

Dr. Jack Cush reviews highlights from the journals and news this week on RheumNow.com.

  1. Injection of nanoparticle peptides carrying siRNA that inhibit NF-κB may benefit osteoarthritic joints https://t.co/6KlbF1Dlkr
  2. FDA grants breakthrough status to Actemra for Rx of giant cell arteritis. Breakthrough=expediated processing by FDA. https://t.co/y6rDS9gr0I
  3. IRAK3 rs11541076 polymorphism yields 33% increase odds of response to TNFi. NLRP3 rs461266 has 25% fewer responses. https://t.co/qIuf7dJKU3
  4. Do we need Gout Disease Activity Score (GAS)? Omeract has one based on #Flares last 12mos,  SUA, 10cmVAS, TJC, SJC(0-66) https://t.co/27AWesZDvP
  5. TaSER study 111 RA patients, shows US driven T2T treatment strategy was no more effective than DAS28 driven T2T outcomes https://t.co/3Vjq4pWODp
  6. Systematic review of gout shows that allopurinol Rx significantly lowers systolic & diastolic BP & creatinine levels https://t.co/F1LbrU1UUA
  7. Metanalysis shows CCP superior to RF: sensitivity (67 v 69%), specificity (96 v 86%), PLR (12.6 v 4.9), & erosions https://t.co/D9GedlXRZe
  8. Ortho literature says surgical excision of RA nodules is effective. In my experience the complication rate is high!… https://t.co/TwjN1GUeMx
  9. CDC Says the Prevalence of Severe Joint Pain is Rising 
  10. The Arthritis Spectrum after Lyme Infection - Something New 
  11. Anti-IL-23 Guselkumab Beats Adalimumab in Severe Psoriasis 
  12. BUILD Study - Baricitinib Shows Rapid Efficacy (ACR20: 62 vs 39%) and X-ray Protection

Disclosures
The author has received research/grant financial support on this subject
The author has received compensation as an advisor or consultant on this subject

Add new comment

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

×